For EGFR Oligo-Mets NSCLC, TKIs and radiation therapy.

Published Date: 29 Jul 2023

What advantages might adding radiotherapy to conventional TKI therapy bring about for the treatment of EGFR-mutated NSCLC?

Read Full News

Latest News

S3 Episode 5: The Future of Endometrial Cancer Pathology

Drs Ursula A. Matulonis and Marisa R. Nucci discuss the future of AI and pathology and how genetics and genomics play a role in the diagnosis of endometrial cancer.

What ASCO 2026 Taught Us About Scaling AI in Cancer Care

The next era of oncology AI won’t be won by the best model, the highest benchmarks, or flashiest press release. It will be won by the most reliable pathway to deployability.

Practice-Changing Data in GI Oncology

From ASCO 2026, Dr Mark Lewis breaks down a 'transformational' shift in GI oncology, from the historic RAS revolution to biomarker-driven advances in colon cancer.

S1 Episode 1: Can Primary Care Catch MASLD Before Cirrhosis?

MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

S1 Episode 2: Recurrent UTIs in Older Women

Drs Anne Lenore Ackerman and Melissa Kaufman discuss recurrent UTIs in older women and its association with genitourinary syndrome of menopause.

Herpes Simplex Virus Esophagitis in an Immunocompetent Man

Severe esophageal symptoms that do not respond to standard treatment may warrant endoscopic evaluation and targeted diagnostic testing.

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Latest News

Drs Ursula A. Matulonis and Marisa R. Nucci discuss the future of AI and pathology and how genetics and genomics play a role in the diagnosis of endometrial cancer.

The next era of oncology AI won’t be won by the best model, the highest benchmarks, or flashiest press release. It will be won by the most reliable pathway to deployability.

From ASCO 2026, Dr Mark Lewis breaks down a 'transformational' shift in GI oncology, from the historic RAS revolution to biomarker-driven advances in colon cancer.

MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

Drs Anne Lenore Ackerman and Melissa Kaufman discuss recurrent UTIs in older women and its association with genitourinary syndrome of menopause.

Severe esophageal symptoms that do not respond to standard treatment may warrant endoscopic evaluation and targeted diagnostic testing.

News All Time

Is Alcohol Part of a Healthy Lifestyle?

Cardiologist Chris Labos takes a look at the French paradox and the J-shaped curve — which tout moderate alcohol as healthy — and asks is the amount of alcohol you should drink really zero?

S3 Episode 4: Investigator-Initiated Clinical Trials in Endometrial Cancer

Drs Ursula A. Matulonis and Stephanie Lheureux discuss the importance of investigator-initiated clinical trials in endometrial cancer, research on carcinosarcoma, and ctDNA.

Biomarkers for Cardiovascular Drug Development

A proposal for a context-of-use framework in which circulating biomarkers are assessed along 2 converging “evidence lanes”: analytical readiness and clinical or statistical validation.

T2* MRI Maps Iron in Finger Soft Tissue in Microvasculopathy

Quantitative T2* MRI is feasible and reproducible for detecting microvasculopathy-related iron deposition in the soft tissues of the fingers.

S4 Episode 4: How Confident Should We Be in Psoriasis Biosimilars?

Join Drs Steven Feldman and Jonathan Kay as they examine the data on safety, switching, and confidence in psoriasis biosimilars.

10 Medical Breakthroughs Transforming Clinical Care

CRISPR cures for sickle cell disease, gene therapy for hemophilia A, and expanding CAR T cell uses point to a new era of potentially curative, personalized treatments.

Imaging and Staging Essentials in Uveal Melanoma

Dr Teresa Amaral reviews new uveal melanoma guidelines, focusing on AJCC 8th Edition staging, the Liverpool prognostic tool, and the essential role of BAP1 and PRAME expression.

Vaccinated Woman With COVID Rebound After Ensitrelvir

A possible first case of COVID recurrence after ensitrelvir: a vaccinated woman whose antigen levels fall and then rebound, with symptoms returning 1 day after treatment.

Optimizing UC Therapy in the Presence of Comorbidities

Dr Corey Siegel discusses the importance of individualized therapy selection for ulcerative colitis in the presence of comorbidities.

ESMO Update: New Guidance for Rare Uveal Melanoma

Dr Teresa Amaral breaks down the essential new guidelines for uveal melanoma. Stay ahead of the latest standards in patient care.

A New Ultrapotent Opioid Emerges: What Is Cychlorphine?

Dr Robert Glatter speaks with toxicologist Dr Lewis Nelson about cychlorphine, a newly emerging synthetic opioid linked to fatal overdoses, and what clinicians should understand about detection, naloxone response, and the evolving drug landscape.

Soccer ‘Headers’ Acutely Raise Brain Damage Biomarkers

Study findings are concerning, but will the world’s most popular sport ban the practice of heading the ball?

Lipid Guidelines: Four Major Concerns

Too many Class I recommendations lacking supporting data from randomized trials and intellectual conflicts of interest are among John Mandrola’s complaints about the ACC/AHA guidelines on dyslipidemia.

Canadian EHR Interoperability Weak, Uneven, Harming Patients

Most Canadian physicians use electronic health records, but a lack of connectivity means that patient health information remains siloed across different software programs.

Angiolipoleiomyoma Masquerading as Leiomyoma in a Woman

A 45-year-old woman with a 2-year vaginal foreign body sensation and constipation has a large posterior vaginal wall mass; a biopsy suggests leiomyoma, but excision reveals angiolipoleiomyoma.

Beyond CAR-T: The Rising Potential of Natural Killer Cells

Prof David Kerr explores gene-edited NK cells and allogeneic banks as a potent, ‘off-the-shelf’ alternative to autologous CAR-T infusions.

Recommended News For You

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Smart exercise planning could boost recovery for people with cancer

Alternative Medicine for Breast Cancer: Study Raises Concern

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

Recommended Articles For You

Clinical Methods in Hematology and Quality Improvement 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Inner Thoughts of Leonard Bernstein, the "Maestro".

2.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

3.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

4.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

5.

A promising medication could slow brain tumors in children.

1.

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025

2.

Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies

3.

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances

4.

Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases

5.

Generative AI for Adaptive Oncology Trial Design

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

4.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot